Stepwise Approach Versus Linear Ablation in Patients With Recurrence of Persistent Atrial Fibrillation
Launched by DEUTSCHES HERZZENTRUM MUENCHEN · Oct 26, 2010
Trial Information
Current as of June 26, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with recurrence of symptomatic persistent atrial fibrillation after at least one ablation procedure,
- • with the last ablation procedure at least 3 months ago.
- • at least one unsuccessful attempt of antiarrhythmic drug
- • oral anticoagulation for at least 4 weeks prior to ablation
- Exclusion Criteria:
- • LA thrombus
About Deutsches Herzzentrum Muenchen
Deutsches Herzzentrum München (German Heart Center Munich) is a leading institution in cardiovascular medicine, dedicated to advancing research, treatment, and education in heart health. Affiliated with the Technical University of Munich, the center specializes in innovative clinical trials aimed at improving diagnostic and therapeutic approaches for heart diseases. With a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to patient-centered care, Deutsches Herzzentrum München is at the forefront of developing novel interventions and enhancing clinical outcomes in cardiovascular health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, , Germany
Patients applied
Trial Officials
Isabel Deisenhofer, MD
Study Chair
Deutsches Herzzentrum München
Sonia Ammar, MD
Principal Investigator
Deutsches Herzzentrum München
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials